Aegerion Pharma (AEGR) Tops Q3 EPS by 8c

Aegerion Pharma (NASDAQ: AEGR) reported Q3 EPS of ($0.34), $0.08 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $67.3 million versus the consensus estimate of $59.72 million.

Aegerion Pharma sees FY2015 revenue of $230-245 million, versus the consensus of $239.1 million.

For earnings history and earnings-related data on Aegerion Pharma (AEGR) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• UBS Reiterates Buy Rating on KB Home (KBH) Amid Transition Back to Built-to-Order
• AutoZone (AZO) PT Lowered to $4,230 at UBS Following 'Underwhelming' Q4 Print